Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group

Mikami, Mikio; Aoki, Yoichi; Sakamoto, Masaru; Shimada, Muneaki; Takeshima, Nobuhiro; Fujiwara, Hisaya; Matsumoto, Takashi; Kita, T; Takizawa, Ken

doi:10.1097/igc.0000000000000202

Cited by 43 publications

(42 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,19 Therefore, half of all Japanese gynecologic oncologists chose RH for stage IIB patients with non-SCC, despite the fact that only a third selected RH for those with SCC. 20 Although an international collaborative meta-analysis of neoadjuvant chemotherapy (NAC) also reported that NAC reduced the need of adjuvant radiotherapy by decreasing pathological risk factors and distant metastasis, but failed to improve survival compared with RH without NAC, 21 Neoadjuvant chemotherapy followed by RH is also permitted as one of the optional strategies for stages IB2, IIA2, and IIB patients with cervical cancer in Japan.…”

mentioning

confidence: 99%

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

Kojima

Shimada

Mikami

et al. 2018

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

Kojima

Shimada

Mikami

et al. 2018

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…A questionnaire study in Japan showed that 33 of 166 institutions in the Japanese Gynecologic Oncology group use adjuvant chemotherapy (CT) for patients with risk factors (17), but a comparison of the efficacy of adjuvant CT and RT/CCRT for patients with AC has not been conducted. Therefore, we added this comparison through a retrospective review of outcomes in 45 AC cases with pathological risk factors treated with radical surgery followed by adjuvant CT or RT/CCRT (additional study).…”

Section: Introductionmentioning

confidence: 99%

Adjuvant therapy after radical surgery for stage IB–IIB cervical adenocarcinoma with risk factors

Seki

Tanabe

Nagata

et al. 2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: Patients with adeno/adenosquamous carcinoma may have a poorer prognosis than patients with squamous cell carcinoma. Radiotherapy and concurrent chemoradiotherapy are used as adjuvant therapies for cervical cancer, regardless of the histological subtype. The aim of this study was to investigate the prognostic outcome of adjuvant therapy for patients with adeno/ adenosquamous carcinoma with pathological risk factors. Methods: The medical records of 135 patients with stage IB-IIB cervical cancer with squamous cell carcinoma or adeno/adenosquamous carcinoma who underwent primary surgery followed by adjuvant therapy were retrospectively reviewed. Patients with a pathologically confirmed bulky tumor (≥4 cm), nodal metastasis and/or parametrium invasion were included in the study. Results: The median follow-up period was 48 (1-132) months. Of the 135 patients, 90 with squamous cell carcinoma and 23 with adeno/adenosquamous carcinoma were treated with adjuvant radiotherapy and concurrent chemoradiotherapy (SCC-RT/CCRT and AC-RT/CCRT groups), and 22 with adeno/adenosquamous carcinoma were treated with adjuvant systemic chemotherapy (AC-CT group). There were no significant differences in clinicopathological factors between the SCC-RT/CCRT and AC-RT/CCRT groups and between the AC-RT/CCRT and AC-CT groups. Progression-free survival was significantly shorter in the AC-RT/CCRT group compared to the SCC-RT/CCRT group (P = 0.002). Adeno/adenosquamous carcinoma histology and multiple lymph node metastasis were independent prognostic factors for shorter progression-free survival in patients treated with adjuvant radiotherapy and concurrent chemoradiotherapy. Progression-free survival was also significantly shorter in the AC-RT/CCRT group compared to the AC-CT group (P = 0.026). Conclusions: Adjuvant radiotherapy and concurrent chemoradiotherapy may be less effective for patients with adeno/adenosquamous carcinoma than for those with squamous cell carcinoma. Adjuvant systemic chemotherapy may be beneficial for adeno/adenosquamous carcinoma and further studies are warranted.

show abstract

“…17 One of the reasons why Japanese patients with FIGO stage IIB cancer often underwent surgery was differences in the surgical procedure. In Japan, RH with the Okabayashi procedure, 4 which involves the removal of a vaginal cuff of at least 2 cm and the total resection of parametrial tissue, has been adopted for FIGO stage IIB cancer.…”

Section: Discussionmentioning

confidence: 99%

Propensity Score Analysis of Radical Hysterectomy Versus Definitive Chemoradiation for FIGO Stage IIB Cervical Cancer

Tomita¹,

Mizuno

Makita

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Surgical Principles for Managing Stage IB2, IIA2, and IIB Uterine Cervical Cancer (Bulky Tumors) in Japan: A Survey of the Japanese Gynecologic Oncology Group

Abstract: This survey provided information regarding the current surgical management of uterine cervical cancer (stages IB2, IIA2, and IIA) in Japan.

Cited by 43 publications

References 9 publications

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

Adjuvant therapy after radical surgery for stage IB–IIB cervical adenocarcinoma with risk factors

Propensity Score Analysis of Radical Hysterectomy Versus Definitive Chemoradiation for FIGO Stage IIB Cervical Cancer

Contact Info

Product

Resources

About